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Abstract  
Since the 1980s coronary artery bypass grafting (CABG) 
has been considered as the gold standard for treating left main 
disease. The continuous evolution of tools and techniques 
concerning coronary angioplasty and the advent of drug-eluting 
stents (DES) have established percutaneous coronary 
intervention (PCI) as a possible alternative to CABG. Initial 
randomized studies that were conducted during the previous 
decade, with main representative the SYNTAX study, compared 
conventional CABG to PCI with first generation DES and 
showed non-inferiority regarding hard clinical outcomes. The 
results of two randomized studies comparing CABG versus PCI 
with second generation DES were simultaneously published in 
the end of 2016 to further support PCI as a credible alternative 
to CABG for patients with left main disease with low and 
intermediate SYNTAX scores. A Heart Team is indispensable to 
best evaluate the anatomic parameters of coronary lesions, the 
clinical variables and the technical possibilities regarding 
disease complexity in order to define the ideal revascularization 
strategy for each patient in the elective setting. Percutaneous 
treatment for left main disease has been increasingly performed 
during the last decade, since the procedural steps and optimal 
techniques for left main PCI are nowadays standardized and well 
described in expert consensus documents and therefore should 
be respected and applied in order to optimize patient outcomes. 
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INTRODUCTION  
Coronary artery bypass grafting (CABG) has been 
considered as the gold standard for treating left main (LM) 
disease since the 1980s, after clinical studies had proven 
its superiority over medical treatment concerning 
mortality.1 During the first two and a half decades of 
percutaneous coronary intervention (PCI) the results of 
CABG could not be challenged by simple balloon 
angioplasty and bare-metal stents. However, the 
continuous evolution of tools and techniques and the 
arrival of drug-eluting stents (DES) have progressively 
established PCI as a possible alternative to CABG. 
Significant LM lesions represent about 5% of the 
lesions revealed at coronary angiography and are 
predominantly distal affecting the left main bifurcation (in 
almost 4 out of 5 of cases).2 In up to 25% of cases, a distal 
trifurcation exists due to the presence of an intermediate 
branch. It is estimated that the LM usually supplies more 
than 75% of the left ventricular myocardium in cases of 
right dominant coronary circulation.3 Importantly, the size 
of the normal LM and its bifurcation into the left anterior 
descending (LAD) and the left circumflex (LCX) is 
predictable using fractal geometry and Finet’s law (the LM 
diameter roughly equals the two thirds of the sum of the 
proximal LAD diameter plus the proximal LCX 
diameter).4 The LM has unique anatomic features which 
should be taken into account during clinical practice and 
intervention.5   
EVIDENCE-BASE FOR LEFT MAIN PCI  
Four randomized studies from the previous decade 
which compared conventional CABG to PCI with first 
generation DES and showed non-inferiority have 
contributed to the current recommendations and clinical 
practice regarding LM revascularization.6-9 Most 
importantly, the subgroup analysis of 705 patients with 
LM disease of the SYNTAX study that randomized 
patients to CABG or PCI with a first generation paclitaxel-
eluting stent (Taxus Express, Boston Scientific) showed 
comparable results for the two strategies concerning the 
advent of major acute cardiovascular events (MACE) 
composite end-point (death, MI, cerebrovascular accident 
and repeated revascularization) at 1 year follow-up 
(CABG 13.7% vs PCI 15.8%, p=0.44).8 At 5-year follow-
up there was no significant difference in mortality (CABG 
14.6% vs PCI 12.8%, p=0.53) and MI (CABG 4.8% vs PCI 
8.2%, p=0.10), while CABG was associated with a higher 
incidence of stroke (CABG 4.3% vs PCI 1.5%, p=0.03) 
and a lower risk of repeated revascularization (CABG 15.5 
%  vs PCI 26.7%, p = 0.001), but without significant 
difference in the composite MACE outcome (CABG 31% 
vs PCI 36.9%, p = 0.12).10,11 Furthermore the results for 
MACE were comparable for the two techniques among 
patients with a SYNTAX score <22 (CABG 30.4% vs PCI 
31.5%, p = 0.74) and among those with SYNTAX score 
23-32 (32.7% vs 32.3%, p = 0.88). Among patients with a 
SYNTAX score >32 CABG was associated with favorable 
results regarding mortality (CABG 14.1% vs PCI 20.9%, 
p=0.11) and a significantly lower rate of repeat 
revascularization (11.6% vs 34.1%, p< 0.001), but with a 
higher risk of stroke (4.9% vs 1.6%, p=0.13).10,11  
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The results of the SYNTAX study validated the 
SYNTAX score that had been proposed on 2005.8,12 It is a 
score calculated according to the anatomic complexity of 
coronary artery disease and thus used to evaluate the risk 
and possible outcome of PCI, according to the results of 
SYNTAX study. This score however has several 
drawbacks: its reproducibility is difficult, it is time 
consuming to calculate, it does not include clinical 
variables or ischemia documentation and its prognostic 
value is not calibrated.13 The current recommendations for 
myocardial revascularization are largely based on the 
results of the SYNTAX study and propose the use of the 
SYNTAX score in order to select the most suitable 
revascularization strategy for each patient.14 Yet, it is 
logical that in clinical practice decisions cannot be based 
only on a score that describes the anatomic complexity of 
coronary artery disease, but also in multiple other clinical 
parameters. The advent of the second-generation DES that 
clearly outperformed first-generation DES in multiple 
clinical studies regarding the rates of restenosis and stent 
thrombosis, along with the progress in the techniques and 
tools of PCI, have created doubt about the validity of the 
guidelines which are based on results of studies conducted 
during the previous decade.  
The revascularization of significant LM lesions holds 
naturally a class IA recommendation according to the last 
European guidelines for myocardial revascularization 
published in 2014.14 According to the abovementioned 
data in the same guidelines regarding severe LM disease, 
PCI holds a class IB recommendation for patients with a 
SYNTAX score <22, a class IIA recommendation for 
patients with SYNTAX score 22-32 and finally a class III 
recommendation for patients with SYNTAX score >32, 
while CABG holds a class IB recommendation irrespective 
of the SYNTAX score.14  
At the end of 2016, two very significant new 
randomized studies comparing CABG to PCI with second 
generation DES were simultaneously published, EXCEL 
and NOBLE (Table 1 shows their main results along with 
those of SYNTAX LM). The EXCEL study comprised 
1905 patients presenting with LM disease and had a non-
inferiority design.15 The DES that was used in the PCI arm 
was a second-generation fluoropolymer-based cobalt–
chromium everolimus-eluting stent (Xience, Abbott) and 
patients with a SYNTAX score <32 were included. The 
EXCEL investigators used a contemporary second-
generation DES, which has shown a very low incidence of 
stent thrombosis and restenosis and they frequently used 
intravascular ultrasonography (IVUS) to guide stent 
placement and optimization. In the other study arm 
contemporary surgical techniques were used with arterial 
revascularization procedures and off-pump CABG being 
performed in many patients.  
The primary end-point was a composite of MACE 
including all cause death, stroke and MI. At 3 years the 
primary end-point was met in 15.4% of the PCI arm and in 
14.7% of the CABG arm patients, leading to the 
conclusion that PCI was non-inferior to CABG (p=0.02 for 
non-inferiority). Of note, the secondary end-points of 
death, stroke or MI at 30 days were met in 4.9% patients 
of the PCI arm and in 7.9% of patients of the CABG arm 
(p < 0.001 for non-inferiority, p = 0.008 for superiority). 
This trend was reversed after the first month with MACE 
found in 23.1% of patients in the PCI arm and 19.1% of 
patients in the CABG arm (p = 0.01 for non-inferiority, p 
= 0.10 for superiority).15 
The NOBLE study had also a non-inferiority design 
that randomized 1201 patients with left main disease to 
CABG or PCI.16 The primary MACE end-point included 
repeated revascularization, non-procedural MI, stroke and 
all-cause mortality. In contrast to EXCEL this study 
concluded that CABG was superior to PCI. At 5 years 
MACE were met in 28% of PCI patients and in 18% of 
CABG patients (hazard ratio 1.51, 95% confidence 
interval 1.13-2.0) which was beyond the non-inferiority 
limit (p=0.044). These results were driven by an increased 
risk of non-procedural MI (p=0.004) and repeated 
revascularizations (p=0.03) in the PCI arm, with the 
repeated revascularizations being included in the primary 
end point in NOBLE trial but not in EXCEL.15,16  
These apparently contradictory results between the 
EXCEL and NOBLE studies that try to find the answer to 
the same clinical question are explained by the differences 
regarding their design. The EXCEL study had a shorter 
follow-up period and its primary composite end-point did 
not include repeated revascularizations (that are known to 
be systematically met more often after PCI compared to 
CABG) but included procedural MIs (defined by troponin 
elevations of >5 times above the upper limit of normal 
which are often met after CABG). Under these conditions 
PCI was found non-inferior to CABG for the 
revascularization in case of LM disease.  
Due to their similar design and simultaneous 
publication, the different results of these two trials 
generated a lot of discussion. In particular, it has been 
speculated that differences in primary endpoint selection, 
differences in periprocedural MI definitions and available 
follow-up lengths might have played a major role. In 
addition, different DES were used (e.g., a thin-strut cobalt–
chromium everolimus-eluting stent in the EXCEL trial vs 
a thicker-strut stainless steel biolimus-eluting stent in 
about 90% of NOBLE trial patients). The possible 
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relevance of this issue is suggested by a striking difference 
in the definite stent thrombosis rate observed in the two 
trials (0.7% in EXCEL and 3% in NOBLE). Most 
importantly it should be noted that despite the 
discrepancies in these two studies with new generation 
DES the repeated revascularization rates in the PCI arm 
were almost two times inferior compared to the PCI arm of 
SYNTAX study, a sign that confirms the improved 
performance of the new generation DES.  
Recently, Palmerini et al published the results of a 
meta-analysis of all 6 available trials including 4.686 
randomized patients (also collecting key missing data in 
order to enable subgroup analyses). After a median follow-
up of 39 months, there were no significant differences 
between PCI vs CABG in the risk of all-cause mortality or 
cardiac mortality. Unsurprisingly long-term cardiac death 
differed in relation to angiographic complexity, such that 
the relative risk for mortality tended to be lower with PCI 
compared to CABG among patients in the lower SYNTAX 
score tertile, similar in the intermediate tertile, and higher 
in the upper SYNTAX score tertile. Finally, and 
consistently with previous results, both procedures 
resulted in similar long-term composite rates of death, MI, 
or stroke, with PCI offering an early safety advantage and 
CABG demonstrating greater durability.17  
LEFT MAIN PCI STRATEGY AND TECHNIQUE 
ISSUES  
According to the European guidelines, myocardial 
revascularization is indicated for patients with LM 
angiographic stenosis >50% and documentation of 
myocardial ischemia.14  When LM stenosis severity is 
uncertain from angiography, it should be assessed without 
hesitation in the catheterization laboratory with the use of 
adjunctive devices for intravascular imaging or 
physiologic assessment. Among various modalities, 
intravascular ultrasound minimal lumen area >6 mm2 and 
FFR >0.80 are well-known acceptable criteria for 
deferring left main revascularization.18,19 
European guidelines highlight the critical role of the 
multi-disciplinary Heart Team in the treatment decision for 
stable or stabilized patients with unprotected LM disease 
in whom revascularization is being planned electively or 
semi-electively.14 In the emergency setting, however, 
myocardial revascularization must be performed as soon 
as possible, since CABG is usually not a viable option.  
Of note, the need for hemodynamic support devices is 
anticipated to be higher for patients with severe LM 
disease, either in the setting of elective PCI (especially in 
cases with depressed left ventricular function) or in 
emergency cases due to acute coronary syndromes. In 
some circumstances, rapid and effective deployment of 
hemodynamic support devices can be life-saving during 
complications of left main interventions. Accordingly, it is 
important that these are immediately available and can be 
inserted and activated quickly, which requires a high level 
of organization and sufficiently trained staff in the cath lab 
beyond the physician skills and experience. An LM PCI 
example is presented in Figures 1-3.   
 Figure 1. LM PCI example. Critical ostial stenosis of a diffusely 
atheromatous short LM (1) treated with transradial PCI. The 
lesion being resistant is pre-dilated with progressively increasing 
in diameter non-compliant balloons (2-6) and finally with a 
scoring balloon (7). The result is satisfactory and the LM is now 
sufficiently prepared for stenting, yet with a linear dissection 
throughout its length extending into the proximal LAD (8). Τhe 
next procedural steps are shown in Fig. 2. LAD = left anterior 
descending; LM = left main  
 Figure 2. Left main PCI example (continued). A DES is 
positioned to cover the LM from the ostium to the proximal LAD 
and deployed (1,2). It is then post-dilated with a large non-
compliant balloon until the carina of the LM bifurcation in order 
to perform the proximal optimization technique (POT) to obtain 
a good apposition of the stent in the LM (3), a kissing balloon 
inflation is performed (4) and a final POT is repeated as in 3. The 
balloons used for each of these procedural steps must be 
appropriately sized non-compliant balloons in order to obtain a 
good angiographic result as in this case (5,6).  
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The selection of a DES that will adapt correctly to the 
LM anatomy is recognized as a critical step for successful 
PCI. Accordingly, the individual patient’s LM anatomy 
assessment by IVUS is strongly recommended whenever 
angiography is unclear and there are doubts about stent 
sizing (Fig. 3). In LM ostium/mid-shaft disease where the 
DES will not extend distally beyond the bifurcation it 
should be selected according to the LM diameter. 
Knowledge of DES platform characteristics is pivotal 
during LM stenting procedures. DES from different 
manufactures are available with different diameter ranges, 
thus large diameter stents whose nominal range falls within 
the typical LM size (4.5-5 mm) should be readily available 
together with non-compliant balloons of diameters more 
than 4mm (mainly 4.5mm and 5mm, but up to 6mm could 
be needed in some cases).  
 
 Figure 3. Left main PCI example (continued). The diffusely 
diseased LM with a critical ostial stenosis (A) has been treated 
with PCI to obtain a good angiographic result (B, C). 
Intravascular ultrasound control verified good stent expansion 
and apposition in the proximal LAD (1), with good opening of 
the stent cells at the LCX ostium (2) and also good stent 
expansion and apposition in the LM body (3).  
Bench tests have confirmed the ability of different 
contemporary DES platforms with a nominal size of 3-4 
mm to maintain structural integrity when expanded to 
higher diameters, but to a limit more or less defined for 
each platform.20  In the more common situation of PCI to 
tackle bifurcation lesions, the LM coverage must be 
achieved with the same DES which is implanted into either 
the LAD or the LCX and consequently the stent size is 
selected according to the distal vessel diameter, so that 3-
4 mm DES are usually considered. As a next pivotal step 
stent expansion in the LM is recommended according to 
the proximal optimization technique (POT) and by using 
an appropriately sized non-compliant balloon at high 
pressure for post-dilation.21 Whether and when it is 
necessary to perform stent side-cell re-crossing, dilatation 
and eventual kissing balloon inflation after POT is debated 
and examined in a case-by-case basis. Side branch ostium 
angiographic stenosis after main vessel stenting may be the 
result of carina shift, a phenomenon that may not signify 
functional perturbation. According to expert consensus as 
a general principle kissing balloon inflation should be 
undertaken if a suboptimal result in the side branch ostium 
is clearly recognized or the possibility exists for 
downstream PCI in the future.21  
Provisional stenting is the recommended technique for 
distal LM disease not involving both branches and usually 
one stent is needed (Fig. 1-3). When both LAD and LCX 
ostia are significantly diseased, the choice of stent 
technique is of great importance, it should depend on the 
individual patient’s anatomical characteristics and the 
operator’s skill, but certainly the chances of needing two 
stents for both LM branches are quite high. The expert 
consensus is that the vast majority of true bifurcation 
anatomies can be approached using a stepwise provisional 
technique which includes the potential to end with double 
stenting if needed. Expert consensus suggests that T/TAP 
or culotte are adequate techniques for bail-out side branch 
stenting. Whenever a second stent is implanted, the 
performance of high-pressure kissing inflation is 
mandatory and may benefit from a sequential strategy 
where the two balloons are firstly individually dilated to 
high pressures (to ensure ostial LAD and LCX expansion), 
followed by a simultaneous balloon inflation at lower 
pressures (to avoid LM overstretch). Since kissing balloon 
inflation is associated with proximal stent segment oval 
shape deformation, repeat final POT to obtain circular 
stent expansion of the DES is advisable, whenever long 
kissing balloon overlap in the left main stent occurs.21 
Among different techniques for elective double stenting, 
DK-Crush has become increasingly popular since it 
reduces the final kissing inflation failure rate as compared 
with the classic stent crush technique. A recent trial 
conducted in centers experienced with this technique 
reported better one-year target vessel failure rates as 
compared with provisional stenting.22  
Intracoronary imaging (IVUS or optical coherence 
tomography) and functional (pressure wire-based) 
assessments are useful to optimize left main PCI, since 
there is a relationship between suboptimal LM PCI results 
and adverse clinical outcomes. As compared with 
angiographic guidance, IVUS-guided LM stenting has 
been found to be associated with a clinically detectable 
benefit, so that its use is strongly recommended.23 For 
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instance, IVUS was extensively used in the EXCEL and 
NOBLE trials 15,16 
Intensive follow-up strategies should be considered for 
patients who have undergone successful LM PCI, 
especially when complex procedures with double-stent 
techniques have been used.   
Conclusions  
For the revascularization in case of LM disease PCI is 
supported by robust clinical data as a viable alternative to 
CABG among patients with low and intermediate 
SYNTAX scores. However, CABG still holds a long-term 
benefit, mainly concerning the need for repeated 
revascularization procedures. A Heart Team is 
indispensable to best evaluate the anatomic parameters of 
coronary lesions, the clinical variables and the technical 
environment in order to define the ideal revascularization 
strategy for each patient. When LM PCI is decided it 
should be performed with great attention to technical 
details and a low threshold for intravascular imaging 
guidance in order to optimize the result and patient 
outcomes.   
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Table 1. Most important randomized studies that define the current role of PCI for left main (LM) disease. 
 
Study Year Patients DES 
Generation 
DES type Primary endpoint 
(PCI vs CABG) 
Secondary endpoints 
(PCI vs CABG) 
SYNTAX LM11 
 
2010 
 
705 
 
First TAXUS At 1 year: 
 
Death, CVA, MI, or 
repeat 
revascularization: 
15.8% vs. 13.7%, 
p=NS.  
At 5 years:  
 
1. Death, CVA, MI, or repeat revascularization:  
36.9% vs. 31%, p=NS  
2. Death/CVA/MI: 19% vs 20.8%, p=NS  
3. Death: 12.8% vs 14.6%, p=NS  
4. CVA: 1.5% vs 4.3%, p=0.03  
5. MI: 8.2% vs 4.8%, p=0.10  
6. Repeat revascularization: 26.7% vs 15.5%, 
p<0.001  
EXCEL15 
 
2017 1905 
 
Second XIENCE 
 
At 3 years:  
 
Death, CVA, or MI: 
15.4% vs 14.7%,  
p for non-inferiority = 
0.02, p=NS for 
superiority  
 
At 3 years:  
 
1. Death, stroke, MI, or repeat revascularization: 
3.1% vs 19.1%, p for non-inferiority = 0.01 
2. Death: 8.2% vs 5.9%, p=0.11 
3. CVA: 2.3% vs 2.9%, p=NS 
4. MI: 8.0% vs 8.3%, p=NS 
5. Repeat revascularization:  
12.6% vs 7.5%, p<0.001 
NOBLE16 2017 1201 
 
Second BioMatrix  At 5 years: 
 
Death, CVA, or non-
procedural MI, repeat 
revascularization: 
 29% vs 19%, 
p=0.0066 
At 5 years: 
 
- Death: 12% vs 9%, p=NS 
- CVA: 5% vs 2%, p=0.073 
- Non-procedural MI: 7% vs 2%, p=0.004 
- Repeat revascularization: 16% vs 10%, p=0.032 
CABG = coronary artery bypass grafting; CVA = cerebrovascular accident; DES = drug-eluting stent(s); LM = left main; MI = 
myocardial infarction; NS = non-significant; PCI = percutaneous coronary intervention 
 
 
 
   
